scholarly journals A Robust Bioassay of the Human Bradykinin B2 Receptor that Extends Molecular and Cellular Studies: The Isolated Umbilical Vein

2021 ◽  
Vol 14 (3) ◽  
pp. 177
Author(s):  
François Marceau ◽  
Hélène Bachelard

Bradykinin (BK) has various physiological and pathological roles. Medicinal chemistry efforts targeted toward the widely expressed BK B2 receptor (B2R), a G-protein-coupled receptor, were primarily aimed at developing antagonists. The only B2R antagonist in clinical use is the peptide icatibant, approved to abort attacks of hereditary angioedema. However, the anti-inflammatory applications of B2R antagonists are potentially wider. Furthermore, the B2R antagonists notoriously exhibit species-specific pharmacological profiles. Classical smooth muscle contractility assays are exploited over a time scale of several hours and support determining potency, competitiveness, residual agonist activity, specificity, and reversibility of pharmacological agents. The contractility assay based on the isolated human umbilical vein, expressing B2R at physiological density, was introduced when investigating the first non-peptide B2R antagonist (WIN 64338). Small ligand molecules characterized using the assay include the exquisitely potent competitive antagonist, Pharvaris Compound 3 or the partial agonist Fujisawa Compound 47a. The umbilical vein assay is also useful to verify pharmacologic properties of special peptide B2R ligands, such as the carboxypeptidase-activated latent agonists and fluorescent probes. Furthermore, the proposed agonist effect of tissue kallikrein on the B2R has been disproved using the vein. This assay stands in between cellular and molecular pharmacology and in vivo studies.

Toxins ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 78
Author(s):  
Lachlan A. Bourke ◽  
Christina N. Zdenek ◽  
Edgar Neri-Castro ◽  
Melisa Bénard-Valle ◽  
Alejandro Alagón ◽  
...  

The toxin composition of snake venoms and, thus, their functional activity, can vary between and within species. Intraspecific venom variation across a species’ geographic range is a major concern for antivenom treatment of envenomations, particularly for countries like French Guiana that lack a locally produced antivenom. Bothrops asper and Bothrops atrox are the most medically significant species of snakes in Latin America, both producing a variety of clinical manifestations, including systemic bleeding. These pathophysiological actions are due to the activation by the venom of the blood clotting factors Factor X and prothrombin, thereby causing severe consumptive coagulopathy. Both species are extremely wide-ranging, and previous studies have shown their venoms to exhibit regional venom variation. In this study, we investigate the differential coagulotoxic effects on human plasma of six venoms (four B. asper and two B. atrox samples) from different geographic locations, spanning from Mexico to Peru. We assessed how the venom variation of these venom samples affects neutralisation by five regionally available antivenoms: Antivipmyn, Antivipmyn-Tri, PoliVal-ICP, Bothrofav, and Soro Antibotrópico (SAB). The results revealed both inter- and intraspecific variations in the clotting activity of the venoms. These variations in turn resulted in significant variation in antivenom efficacy against the coagulotoxic effects of these venoms. Due to variations in the venoms used in the antivenom production process, antivenoms differed in their species-specific or geographical neutralisation capacity. Some antivenoms (PoliVal-ICP, Bothrofav, and SAB) showed species-specific patterns of neutralisation, while another antivenom (Antivipmyn) showed geographic-specific patterns of neutralisation. This study adds to current knowledge of Bothrops venoms and also illustrates the importance of considering evolutionary biology when developing antivenoms. Therefore, these results have tangible, real-world implications by aiding evidence-based design of antivenoms for treatment of the envenomed patient. We stress that these in vitro studies must be backed by future in vivo studies and clinical trials before therapeutic guidelines are issued regarding specific antivenom use in a clinical setting.


2012 ◽  
Vol 32 (suppl_1) ◽  
Author(s):  
Shin-Young Park ◽  
Chen Yan ◽  
Bradford C Berk

Introduction— Thioredoxin-interacting protein (TXNIP) is an arrestin-like scaffold protein. We have shown previously that it is necessary for the transactivation of the vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) as well as promoting the migration and survival of endothelial cells (ECs). However, its roles in VEGF-induced angiogenesis and in vivo studies of TXNIP function have not been elucidated. Hypothesis— TXNIP regulates VEGF-mediated angiogenesis through modulation of angiogenic signaling pathways in ECs. Methods and Results— To determine the functions of TXNIP in ECs, we generated endothelial-specific TXNIP knockout (EC-TXNIP KO) mice (TXNIPflox/flox: Tie2-Cre/+). These mice displayed impaired capillary growth of the retinal vasculature compared to control mice. Furthermore, aortic rings from EC-TXNIP KO mice exhibited fewer and shorter vascular sprouts than those in control mice. To investigate the role of TXNIP in the regulation of VEGF-induced angiogenesis, we determined the subcellular localization of TXNIP in human umbilical vein EC (HUVEC). Immunofluorescence and cell fractionation studies revealed that upon VEGF stimulation (10ng/ml). TXNIP translocated from cytoplasm to the plasma membrane. There was a 9 fold increase of membrane associated TXNIP with a peak at 15 minutes compared to non-VEGF treatment cells. We hypothesized that membrane associated TXNIP may modulate VEGFR2 internalization and thereby affect VEGF-induced signaling and angiogenesis. To investigate this, we performed in vitro cell surface biotinylation assays in HUVEC. VEGFR2 internalization was decreased by 65% in TXNIP siRNA knockdown cells compared to control siRNA treated cells following VEGF stimulation. Consistent with this result, VEGF-induced phosphorylation of VEGFR2, PLCγ and ERK1/2 was decreased by knockdown of TXNIP. Significantly, TXNIP knockdown inhibited VEGF-induced proliferation and tube formation in vitro. Conclusion— Our results suggest that TXNIP can modulate VEGF-induced angiogenesis and signaling by regulation of VEGFR2 internalization.


2016 ◽  
Author(s):  
Xavier Charest-Morin ◽  
Hélène Bachelard ◽  
Melissa Jean ◽  
Francois Marceau

Maximakinin (MK), an amphibian peptide possessing the C-terminal sequence of bradykinin (BK), is a BK B2 receptor (B2R) agonist eliciting prolonged signaling. We reinvestigated this 19-mer for species-specific pharmacologic profile, in vivo confirmation of resistance to inactivation by angiotensin converting enzyme (ACE), value as a module for the design of fusion proteins that bind to the B2R in mammalian species and potential activity as a histamine releaser. Competition of the binding of [3H]BK to recombinant human myc-B2Rs in cells that express these receptors revealed that MK possessed a tenuous fraction (<0.1%) of the affinity of BK, despite being only ~10-fold less potent than BK in a contractility assay based on the human isolated umbilical vein. These findings are reconciled by the generation of C-terminal fragments, like Lys-Gly-Pro-BK and Gly-Pro-BK, when the latent MK is incubated with human venous tissue (LC-MS), supporting activation via hydrolysis upstream of the BK sequence. At the rat recombinant myc-B2R, MK had a lesser affinity than that of BK, but with a narrower margin (6.2-fold, radioligand binding competition). Accordingly, MK (10 nM) stimulated calcium transients in cells that expressed the rat receptors, but not the human B2R. Recombinant MRGPRX2, a receptor that mediates cationic peptide-induced mast cell secretion, minimally responded by increased [Ca+2]i to MK at 10 μM. Enhanced green fluorescent protein fused to MK (EGFP-MK) labeled cells that expressed rat, but not human B2Rs. Intravenous MK induced dose-dependent hypotensive, vasodilator and tachycardic responses in anesthetized rats and the effects were antagonized by pretreatment with icatibant but not modified by pyrilamine or enalaprilat. Strong species-specific responses to the toxin-derived peptide MK and its prodrug status in the isolated human vein were evidenced. Accordingly, MK in the EGFP-MK fusion protein is a pharmacophore module that confers affinity for the rat B2R, but not for the human form of the B2R. MK is unlikely to be an efficient mast cell activator, but its resistance to inactivation by ACE was confirmed in vivo.


2016 ◽  
Author(s):  
Xavier Charest-Morin ◽  
Hélène Bachelard ◽  
Melissa Jean ◽  
Francois Marceau

Maximakinin (MK), an amphibian peptide possessing the C-terminal sequence of bradykinin (BK), is a BK B2 receptor (B2R) agonist eliciting prolonged signaling. We reinvestigated this 19-mer for species-specific pharmacologic profile, in vivo confirmation of resistance to inactivation by angiotensin converting enzyme (ACE), value as a module for the design of fusion proteins that bind to the B2R in mammalian species and potential activity as a histamine releaser. Competition of the binding of [3H]BK to recombinant human myc-B2Rs in cells that express these receptors revealed that MK possessed a tenuous fraction (<0.1%) of the affinity of BK, despite being only ~10-fold less potent than BK in a contractility assay based on the human isolated umbilical vein. These findings are reconciled by the generation of C-terminal fragments, like Lys-Gly-Pro-BK and Gly-Pro-BK, when the latent MK is incubated with human venous tissue (LC-MS), supporting activation via hydrolysis upstream of the BK sequence. At the rat recombinant myc-B2R, MK had a lesser affinity than that of BK, but with a narrower margin (6.2-fold, radioligand binding competition). Accordingly, MK (10 nM) stimulated calcium transients in cells that expressed the rat receptors, but not the human B2R. Recombinant MRGPRX2, a receptor that mediates cationic peptide-induced mast cell secretion, minimally responded by increased [Ca+2]i to MK at 10 μM. Enhanced green fluorescent protein fused to MK (EGFP-MK) labeled cells that expressed rat, but not human B2Rs. Intravenous MK induced dose-dependent hypotensive, vasodilator and tachycardic responses in anesthetized rats and the effects were antagonized by pretreatment with icatibant but not modified by pyrilamine or enalaprilat. Strong species-specific responses to the toxin-derived peptide MK and its prodrug status in the isolated human vein were evidenced. Accordingly, MK in the EGFP-MK fusion protein is a pharmacophore module that confers affinity for the rat B2R, but not for the human form of the B2R. MK is unlikely to be an efficient mast cell activator, but its resistance to inactivation by ACE was confirmed in vivo.


2020 ◽  
Vol 01 ◽  
Author(s):  
Salma Batool ◽  
M. Javaid Asad ◽  
Muhammad Arshad ◽  
Rahman Shah Zaib Saleem ◽  
Muhammad Sheeraz Ahmad

Background: Bistorta amplexicaulis is a seasonal herb with several folkloric uses. The plant extract has been shown to possess various activities including antioxidant, anticancer, anti-bacterial, anti-fungal, cardio-protective, anti-atherosclerosis activities. Objective: The aim of the study was to quantify the activity of the plant extract and relate it to the activity of the isolated compounds, gallic acid. Methods: Extraction of the plant was carried out. Then the activity of the extract was compared with its constituent, gallic acid. Cytotoxic potential of the two against human liver cancer cell line (HepG2), breast cancer cell line (MCF-7) and human umbilical vein endothelial cells (HUVEC) was evaluated through MTS assay. Results: The extract had better activity against HepG2 as compared to gallic acid (IC50 29µg/mL vs 37µg/mL). It also provided a better therapeutic window by having lower toxicity for HUVEC cells than gallic acid (IC50 63µg/mL vs 47µg/mL) suggesting the use of the extract over the purified gallic acid for these cells. We also performed the fluorescence study of the rhizome extract in ethanol (REE), methanol (REM), 80% ethanol (80RE), 80% methanol, (80RM) and acetone (RAC). The highest intensity of fluorescence was found in REE with excitation at 394 nm and emission at 421nm. Conclusion: The comparison of gallic acid with ethanolic rhizome extract of B. amplexicaulis reveals important insights about utilizing the plant extract over purified gallic acid. The ethanolic extract also has the potential to be used as autoflouresent drug during in vitro and in vivo studies.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 8-8 ◽  
Author(s):  
Anish V. Sharda ◽  
Joshua Harrison ◽  
Adrian R. Wilkie ◽  
Chao Fang ◽  
Lourdes M. Mendez ◽  
...  

von Willebrand factor (vWF) is an essential plasma hemostatic factor that also participates in pathophysiologic processes such as thrombosis, angiogenesis and tumor metastasis. vWF is synthesized in endothelial cells and stored in specialized granules, Weibel-Palade bodies (WPBs), which exhibit characteristics of secretory granules termed lysosomal-related organelles (LROs). Understanding the mechanisms underlying WPB biogenesis and vWF exocytosis could enable therapeutic modulation of endogenous vWF; however, fundamental aspects of vWF trafficking mechanisms remain unknown. Since biogenesis of lysosomal related organelle 2 (BLOC-2), a complex of HPS3, HPS5 and HPS6 proteins, functions in biogenesis of other LROs such as platelet dense granules and melanosomes, we hypothesized that BLOC-2-dependent endolysosomal trafficking was essential for WPB biogenesis. BLOC-2 was depleted in human umbilical vein endothelial cells (HUVECs) by transduction of cells with lentiviral particles containing HPS6 shRNA. Evaluation of WPBs using multicolor immunofluorescence microscopy showed that the WPBs were immature, granular and abnormally localized to the perinuclear space, as compared to mature, linear-shaped WPBs, distributed peripherally in control cells (number of WPBs &gt; 1.5 µm per cell, HPS6 3±2 vs. control 16±6). Immature WPBs in BLOC-2-depleted HUVECs lacked expression of endosome-derived cargo CD63, but not P-selectin, a synthetic cargo that enters WPBs at the trans-Golgi network. Live cell imaging showed that when BLOC-2 was depleted from HUVECs expressing CD63-GFP, CD63-GFP no longer trafficked to WPBs. Instead, endosome-derived transport tubules were mistargeted to the core of the cell. In comparison, CD63-GFP labeled WPBs intensely in control cells, where direct interaction between endosome-derived transport tubules and WPBs was evident. To identify binding partners of BLOC-2 that facilitate targeting of endosome-derived transport tubules to maturing WPBs, we performed immunoprecipitation of endogenous BLOC-2 in HUVEC lysates and evaluated the captured proteins using mass spectrometry. Several components of the exocyst complex, namely EXOC2, EXOC4 and EXO70, were enriched in BLOC-2 immunoprecipitates. This interaction was confirmed by reciprocal co-immunoprecipitation experiments with HPS6 and EXOC4. Evaluation by immunogold electron microscopy showed that EXOC4 colocalized with HPS6 in HUVECs. EXOC4 depletion using targeted siRNA resulted in WPBs that were immature, granular-appearing and perinuclearly localized, similar to BLOC-2-depleted HUVECs (number of WPBs &gt; 1.5 µm per cell, EXOC4 3±2.5 vs. control 16±5). Overall, these observations indicate that both BLOC-2 and the exocyst complex are critical for endolysosomal trafficking involved in WPB maturation. We next evaluated the roles of BLOC-2 and the exocyst complex in vWF exocytosis. Depletion of BLOC-2 from HUVECs resulted in a 63±3% decrease in thrombin-induced vWF exocytosis and a 41±4% decrease in constitutive vWF exocytosis. Multimer analysis showed loss of high-molecular weight vWF multimers. In vivo studies showed that vWF exocytosis following systemic epinephrine infusion was 158±12% of basal levels in WT mice compared 100±20% in HPS6-/-mice, indicating lack of agonist-induced vWF release in BLOC-2 depleted mice. To evaluate the role of the exocyst complex in vWF release, both EXOC4 and EXO70 were depleted from HUVECS using siRNA. Unexpectedly, depletion of either exocyst complex component augmented thrombin-induced vWF exocytosis (EXOC4 105±21%; EXO70 99±22%). Similarly, endosidin 2, a small molecule inhibitor of EXO70, also augmented vWF exocytosis by 122±26%. These studies demonstrate that both BLOC-2 and the exocyst complex contribute to WPB biogenesis, perhaps working together based on their binding and colocalization on WBPs. However, these two complexes have opposing effects on vWF secretion. While BLOC-2 is necessary for vWF secretion, the exocyst suppresses release. Disclosures Italiano: Platelet Biogenesis: Employment, Equity Ownership; Ionis Research Funding: Research Funding. Flaumenhaft:PlateletDiagnostics: Consultancy, Other: Founder; Relay Therapeutics: Consultancy.


1986 ◽  
Vol 250 (2) ◽  
pp. E121-E124
Author(s):  
T. Kakita ◽  
W. D. Odell

Studies from our laboratory have previously demonstrated sensitive and specific autoregulatory control systems for thyrotropin (TSH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in the rabbit. Because our studies of LH autoregulation showed the feedback regulation acted directly at a pituitary level, the current studies were designed to investigate whether the TSH control system also acted at the pituitary level. Two species-specific TSH assays were employed; a rabbit TSH radioimmunoassay which showed little or no reaction to human TSH, and a human TSH radioimmunoassay which showed little or no reaction to rabbit TSH. Both in vivo and in vitro studies were performed. TRH (thyrotropin-releasing hormone) in doses of 2, 10, and 50 micrograms was injected as an intravenous bolus into thyroidectomized hypothyroid rabbits during continuous perfusion with highly purified human TSH (hTSH) or with saline. In these in vivo studies, TRH-stimulated rabbit TSH (rTSH) secretion was suppressed by hTSH perfusion compared with control saline perfusion. The effect of hTSH was studied in vitro by employing short-term cultured rabbit pituitary cells. When hTSH was added to the incubation medium, TRH-stimulated rTSH secretion was inhibited. From these studies, we conclude that one site of the autoregulatory control for TSH in the rabbit is at the pituitary level. These studies do not exclude a possible additional short-loop feedback control at an hypothalamic level, but such a site of action is not required to explain the autoregulatory phenomenon.


2011 ◽  
Vol 115 (6) ◽  
pp. 1363-1381 ◽  
Author(s):  
Ream Al-Hasani ◽  
Michael R. Bruchas

Opioid receptors have been targeted for the treatment of pain and related disorders for thousands of years and remain the most widely used analgesics in the clinic. Mu (μ), kappa (κ), and delta (δ) opioid receptors represent the originally classified receptor subtypes, with opioid receptor like-1 (ORL1) being the least characterized. All four receptors are G-protein coupled and activate inhibitory G proteins. These receptors form homo- and heterodimeric complexes and signal to kinase cascades and scaffold a variety of proteins.The authors discuss classic mechanisms and developments in understanding opioid tolerance and opioid receptor signaling and highlight advances in opioid molecular pharmacology, behavioral pharmacology, and human genetics. The authors put into context how opioid receptor signaling leads to the modulation of behavior with the potential for therapeutic intervention. Finally, the authors conclude there is a continued need for more translational work on opioid receptors in vivo.


Viruses ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1094 ◽  
Author(s):  
Anna Schachner ◽  
Gabriel Gonzalez ◽  
Lukas Endler ◽  
Kimihito Ito ◽  
Michael Hess

After analyzing 27 new genomes from fowl adenovirus (FAdV) field isolates and so-far unsequenced prototypes, we report the first evidence for recombination in FAdVs. Recombination was confined to species FAdV-D and FAdV-E, accommodating the largest number of, and the intraspecies-wise most differentiated, types. The majority of detected events occurred in FAdV-E, involving segments with parental origin of all constitutive types. Together with the diversity of breakpoints, this suggests widespread recombination in this species. With possible constraints through species-specific genes and diversification patterns, the recombinogenic potential of FAdVs attains particular interest for inclusion body hepatitis (IBH), an important disease in chickens, caused by types from the recombination-prone species. Autonomously evolving, recombinant segments were associated with major sites under positive selection, among them the capsid protein hexon and fiber genes, the right-terminal ORFs 19, 25, and the ORF20/20A family. The observed mosaicism in genes indicated as targets of adaptive pressures points toward an immune evasion strategy. Intertypic hexon/fiber-recombinants demonstrated hybrid neutralization profiles, retrospectively explaining reported controversies on reference strains B3-A, T8-A, and X11-A. Furthermore, cross-neutralization supported sequence-based evidence for interdomain recombination in fiber and contributed to a tentatively new type. Overall, our findings challenge the purported uniformity of types responsible for IBH, urging more complete identification strategies for FAdVs. Finally, important consequences arise for in vivo studies investigating cross-protection against IBH.


2001 ◽  
Vol 21 (7) ◽  
pp. 2435-2448 ◽  
Author(s):  
Moonkyoung Um ◽  
Jun Yamauchi ◽  
Shigeaki Kato ◽  
James L. Manley

ABSTRACT TATA-binding protein (TBP) is a key general transcription factor required for transcription by all three nuclear RNA polymerases. Although it has been intensively analyzed in vitro and inSaccharomyces cerevisiae, in vivo studies of vertebrate TBP have been limited. We applied gene-targeting techniques using chicken DT40 cells to generate heterozygous cells with one copy of theTBP gene disrupted. Such TBP-heterozygous (TBP-Het) cells showed unexpected phenotypic abnormalities, resembling those of cells with delayed mitosis: a significantly lower growth rate, larger size, more G2/-M- than G1-phase cells, and a high proportion of sub-G1, presumably apoptotic, cells. Further evidence for delayed mitosis in TBP-Het cells was provided by the differential effects of several cell cycle-arresting drugs. To determine the cause of these defects, we first examined the status of cdc2 kinase, which regulates the G2/M transition, and unexpectedly observed more hyperphosphorylated, inactive cdc2 in TBP-Het cells. Providing an explanation for this, mRNA and protein levels of cdc25B, the trigger cdc2 phosphatase, were significantly and specifically reduced. These properties were all due to decreased TBP levels, as they could be rescued by expression of exogeneous TBP, including, in most but not all cases, a mutant form lacking the species-specific N-terminal domain. Our results indicate that small changes in TBP concentration can have profound effects on cell growth in vertebrate cells.


Sign in / Sign up

Export Citation Format

Share Document